Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam
CompanyDrug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam

China's Sichuan Kelun-Biotech Wins BTD for Sac-TMT in Non-Squamous NSCLC
CompanyDrug

China’s Sichuan Kelun-Biotech Wins BTD for Sac-TMT in Non-Squamous NSCLC

China's CDE Seeks Feedback on Advanced Therapy Medicinal Products Guidelines
Policy / Regulatory

China’s CDE Seeks Feedback on Advanced Therapy Medicinal Products Guidelines

Philochem Grants RayzeBio Global Rights to OncoACP3 for Prostate Cancer
CompanyDeals

Philochem Grants RayzeBio Global Rights to OncoACP3 for Prostate Cancer

Henlius Biotech Starts Global Phase II Trial for PD-L1 ADC HLX43
CompanyDrug

Henlius Biotech Starts Global Phase II Trial for PD-L1 ADC HLX43

Tawada Healthcare Secures Series A+ Funding Led by Highlight Capital
CompanyDeals

Tawada Healthcare Secures Series A+ Funding Led by Highlight Capital

Merck's Pimicotinib NDA Accepted for Review by China's CDE
CompanyDrug

Merck’s Pimicotinib NDA Accepted for Review by China’s CDE

CSPC Pharma's SYS6040 ADC Gains FDA Clinical Trial Approval
CompanyDrug

CSPC Pharma’s SYS6040 ADC Gains FDA Clinical Trial Approval

State Council Issues Opinions to Advance Shenzhen's Healthcare Reforms
Policy / Regulatory

State Council Issues Opinions to Advance Shenzhen’s Healthcare Reforms

Eisai's Urece Arrives in Shanghai, Poised for Chinese Market Entry
CompanyDrug

Eisai’s Urece Arrives in Shanghai, Poised for Chinese Market Entry

Sanofi to Ship Beyfortus Ahead of RSV Season, Ensuring Global Availability
CompanyDrug

Sanofi to Ship Beyfortus Ahead of RSV Season, Ensuring Global Availability

Boai NKY's LYC001 Receives Clinical Approval in China for Advanced Solid Tumors
CompanyDrug

Boai NKY’s LYC001 Receives Clinical Approval in China for Advanced Solid Tumors